Replies to post #226580 on Biotech Values

[DewDiligence]

COCP sells 4.06M* shares @$0.85—a 25% discount to yesterday’s (inflated) closing price:

https://www.globenewswire.com/news-release/2019/10/31/1938853/0/en/COCRYSTAL-PHARMA-INC-PRICES-3-000-000-UNDERWRITTEN-PUBLIC-OFFERING.html

The stock was -36% today. The company is worthless, IMO.

*Assuming exercise of underwriter’s option.

[DewDiligence]

COCP issues moronic PR (IMO):

https://www.globenewswire.com/news-release/2019/11/11/1944719/0/en/Cocrystal-Pharma-Presents-Positive-Data-from-U-S-Phase-2a-Study-of-CC-31244-Demonstrating-Ability-to-Identify-Patients-More-Likely-to-Respond-to-Ultrashort-Treatment-of-HCV.html

Patients that achieved SVR had significantly higher frequencies of terminally differentiated effector memory CD8+ T cells compared with those who relapsed…

That’s nice, but it doesn’t have anything to do with COCP’s drug or business plan, as far as I can tell.